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Abstract
Background: Reactive oxygen species (ROS) are known mediators of cellular damage in multiple diseases
including diabetic complications. Despite its importance, no comprehensive database is currently available for the
genes associated with ROS.
Methods: We present ROS- and diabetes-related targets (genes/proteins) collected from the biomedical literature
through a text mining technology. A web-based literature mining tool, SciMiner, was applied to 1,154 biomedical
papers indexed with diabetes and ROS by PubMed to identify relevant targets. Over-represented targets in the
ROS-diabetes literature were obtained through comparisons against randomly selected literature. The expression
levels of nine genes, selected from the top ranked ROS-diabetes set, were measured in the dorsal root ganglia
(DRG) of diabetic and non-diabetic DBA/2J mice in order to evaluate the biological relevance of literature-derived
targets in the pathogenesis of diabetic neuropathy.
Results: SciMiner identified 1,026 ROS- and diabetes-related targets from the 1,154 biomedical papers (http://jdrf.
neurology.med.umich.edu/ROSDiabetes/). Fifty-three targets were significantly over-represented in the ROS-diabetes
literature compared to randomly selected literature. These over-represented targets included well-known members
of the oxidative stress response including catalase, the NADPH oxidase family, and the superoxide dismutase family
of proteins. Eight of the nine selected genes exhibited significant differential expression between diabetic and non-
diabetic mice. For six genes, the direction of expression change in diabetes paralleled enhanced oxidative stress in
the DRG.
Conclusions: Literature mining compiled ROS-diabetes related targets from the biomedical literature and led us to
evaluate the biological relevance of selected targets in the pathogenesis of diabetic neuropathy.
Background
Diabetes is a metabolic disease in which the body does
not produce or properly respond to insulin, a hormone
required to convert carbohydrates into energy for daily
life. According to the American Diabetes Association,
23.6 million children and adults, approximately 7.8% of
the population in the United States, have diabetes [1].
T h ec o s to fd i a b e t e si n2 0 0 7w a se s t i m a t e dt ob e$ 1 7 4
billion [1]. The micro- and macro-vascular complica-
tions of diabetes are the most common causes of renal
failure, blindness and amputations leading to significant
mortality, morbidity and poor quality of life; however,
incomplete understanding of the causes of diabetic com-
plications hinders the development of mechanism-based
therapies.
In vivo and in vitro experiments implicate a number of
enzymatic and non-enzymatic metabolic pathways in the
initiation and progression of diabetic complications [2]
including: (1) increased polyol pathway activity leading
to sorbitol and fructose accumulation, NAD(P)-redox
imbalances and changes in signal transduction; (2) non-
enzymatic glycation of proteins yielding “advanced gly-
cation end-products” (AGEs); (3) activation of protein
kinase C (PKC), initiating a cascade of intracellular
stress responses; and (4) increased hexosamine pathway
flux [2,3]. Only recently has a link among these path-
ways been established that provides a unified mechan-
ism of tissue damage. Each of these pathways directly
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gen species (ROS) [2,3].
ROS are highly reactive ions or small molecules includ-
ing oxygen ions, free radicals and peroxides, formed as
natural byproducts of cellular energy metabolism. ROS
are implicated in multiple cellular pathways such as
mitogen-activated protein kinase (MAPK) signaling,
c-Jun amino-terminal kinase (JNK), cell proliferation and
apoptosis [4-6]. Due to the highly reactive properties of
ROS, excessive ROS may cause significant damage to
proteins, DNA, RNA and lipids. All cells express enzymes
capable of neutralizing ROS. In addition to the mainte-
nance of antioxidant systems such as glutathione and
thioredoxins, primary sensory neurons express two main
detoxifying enzymes: superoxide dismutase (SOD) [7]
and catalase [8]. SOD converts superoxide (O2-) to H2O2,
which is reduced to H2O by glutathione and catalase [8].
SOD1 is the main form of SOD in the cytoplasm; SOD2
is located within the mitochondria. In neurons, SOD1
activity represents approximately 90% of total SOD activ-
ity and SOD2 approximately 10% [9]. Under diabetic
conditions, this protective mechanism is overwhelmed
due to the substantial increase in ROS, leading to cellular
damage and dysfunction [10].
The idea that increased ROS and oxidative stress con-
tribute to the pathogenesis of diabetic complications has
led scientists to investigate different oxidative stress
pathways [7,11]. Inhibition of ROS or maintenance of
euglycemia restores metabolic and vascular imbalances
and blocks both the initiation and progression of com-
plications [12,13]. Despite the significant implications
and extensive research into the role of ROS in diabetes,
no comprehensive database regarding ROS-related genes
or proteins is currently available.
I nt h ep r e s e n ts t u d y ,ac o m p r e h e n s i v el i s to fR O S -
and diabetes-related targets (genes/proteins) was com-
piled from the biomedical literature through text mining
technology. SciMiner, a web-based literature mining tool
[14], was used to retrieve and process documents and
identify targets from the text. SciMiner provides a con-
venient web-based platform for target-identification
within the biomedical literature, similar to other tools
including EBIMed [15], ALI BABA [16], and PolySearch
[17]; however, SciMiner is unique in that it searches full
text documents, supports free-text PubMed query style,
and allows the comparison of target lists from multiple
queries.
The ROS-diabetes targets collected by SciMiner were
further tested against randomly selected non-ROS-diabetes
literature to identify targets that are significantly over-
represented in the ROS-diabetes literature. Functional
enrichment analyses were performed on these targets to
identify significantly over-represented biological functions
in terms of Gene Ontology (GO) terms and pathways.
In order to confirm the biological relevance of the
over-represented ROS-diabetes targets, the gene expres-
sion levels of nine selected targets were measured in
dorsal root ganglia (DRG) from mice with and without
diabetes. DRG contain primary sensory neurons that
relay information from the periphery to the central ner-
vous system (CNS) [7,10,18]. Unlike the CNS, DRG are
not protected by a blood-nerve barrier, and are conse-
quently vulnerable to metabolic and toxic injury [19].
We hypothesize that differential expression of identified
targets in DRG would confirm their involvement in the
pathogenesis of diabetic neuropathy.
Methods
Defining ROS-diabetes literature
To retrieve the list of biomedical literature associated
with ROS and diabetes, PubMed was queried using
("Reactive Oxygen Species"[MeSH] AND “Diabetes Mel-
litus"[MeSH]). This query yielded 1,154 articles as of
April 27, 2009. SciMiner, a web-based literature mining
tool [14], was used to retrieve and process the abstracts
and available full text documents to identify targets (full
text documents were available for approximately 40% of
the 1,154 articles). SciMiner-identified targets, reported
in the form of HGNC [HUGO (Human Genome Orga-
nization) Gene Nomenclature Committee] genes, were
confirmed by manual review of the text.
Comparison with human curated data (NCBI
Gene2PubMed)
The NCBI Gene database provides links between Gene
and PubMed. The links are the result of (1) manual
curation within the NCBI via literature analysis as part
of generating a Gene record, (2) integration of informa-
tion from other public databases, and (3) GeneRIF
(Gene Reference Into Function) in which human experts
provide a brief summary of gene functions and make
the connections between citation (PubMed) and Gene
databases. For the 1,154 ROS-diabetes articles, gene-
paper associations were retrieved from the NCBI Gene
database. Non-human genes were mapped to homolo-
gous human genes through the NCBI HomoloGene
database. The retrieved genes were compared against
the SciMiner derived targets. Any genes missed by Sci-
Miner were added to the ROS-diabetes target set.
Protein-protein interactions among ROS-diabetes targets
To indirectly examine the association of literature
derived targets (by SciMiner and NCBI Gene2PubMed)
with ROS and diabetes, protein-protein interactions
(PPIs) among the targets were surveyed. This was based
on an assumption that targets are more likely to have
PPIs with each other if they are truly associated within
the same biological functions/pathways. A PPI network
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Michigan Molecular Interactions (MiMI, http://mimi.
ncibi.org/) database [20] and compared against 100 PPI
networks of randomly drawn sets (the same number of
t h eR O S - d i a b e t e st a r g e ts e t )f r o mH U G O .As t a n d a r d
Z-test and one sample T-test were used to calculate the
statistical significance of the ROS-diabetes PPI network
with respect to the random PPI networks.
Functional enrichment analysis
Literature derived ROS-diabetes targets (by SciMiner
and NCBI Gene2PubMed) were subject to functional
enrichment analyses to identify significantly over-repre-
sented biological functions in terms of Gene Ontology
[21], pathways (Kyoto Encyclopedia of Genes and Gen-
omes (KEGG, http://www.genome.jp/kegg/) [22] and
Reactome http://www.reactome.org/[23]). Fisher’s exact
test [24] was used to calculate the statistical significance
of these biological functions with Benjamini-Hochberg
(BH) adjusted p-value < 0.05 [25] as the cut-off.
Over-represented ROS-diabetes targets
Defining background corpora
To identify a subset of targets that are highly over-
represented within the ROS-diabetes targets, the
frequency of each target (defined as the number of
documents in which the target was identified divided by
the number of total documents in the query) was com-
pared against the frequencies in randomly selected back-
ground corpora. Depending on how the background set
is defined, over-represented targets may vary widely;
therefore, to maintain the background corpora close to
the ROS and diabetes context, documents were selected
from the same journal, volume, and issue of the 1,154
ROS-diabetes documents, but were NOT indexed with
“Reactive Oxygen Species"[MeSH] nor “Diabetes Melli-
tus"[MeSH]. For example, one of the ROS-diabetes arti-
cles (PMID: 18227068), was published in the Journal of
Biological Chemistry, Volume 283, Issue 16. This issue
contained 85 papers, 78 of which were not indexed with
either “Reactive Oxygen Species"[MeSH] or “Diabetes
Mellitus"[MeSH] indexed. One of these 78 papers was
randomly selected as a background document. Three
sets of 1,154 documents were selected using this
approach and processed using SciMiner. Identified tar-
gets were confirmed by manual review for accuracy.
Identifying significantly over-represented targets
ROS-diabetes targets were tested for over-representation
against targets identified from the three background
sets. Fisher’s exact test was used to determine if the fre-
quency of each target in the ROS-diabetes target set was
significantly different from that of the background sets.
Any targets with a BH adjusted p-value < 0.05 in at
least two of the three comparisons were deemed to be
an over-represented ROS-diabetes target. Functional
enrichment analyses were performed on these over-
represented ROS-diabetes targets as described above.
Selecting targets for real-time RT-PCR
A subset of targets were selected for RT-PCR from the
top 10 over-represented ROS-diabetes targets excluding
insulin and NADPH oxidase 5 (NOX5), which does not
have a mouse ortholog. Nitric oxide synthase 1 (NOS1),
the main generator of nitric oxide, ranked at the 15
th
position and was additionally selected for inclusion in
the test set.
Differential gene expression by real-time RT-PCR
Mice
DBA/2J mice were purchased from the Jackson Labora-
tory (Bar Harbor, ME). Mice were housed in a patho-
gen-free environment and cared for following the
University of Michigan Committee on the Care and Use
of Animals guidelines. Mice were fed AIN76A chow
(Research Diets, New Brunswick, NJ). Male mice were
used for this study.
Induction of diabetes
Two treatment groups were defined: control (n = 4) and
diabetic (n = 4). Diabetes was induced at 13 weeks of
age by low-dose streptozotocin (STZ) injections, 50 mg/
kg/day for five consecutive days. All diabetic mice
received LinBit sustained release insulin implants (Lin-
Shin, Toronto, Canada) at 8 weeks post-STZ treatment.
Insulin implants were replaced every 4 weeks, at 12 and
16 weeks post-STZ treatment. At 20 weeks post-STZ
treatment, mice were euthanized by sodium pentobarbi-
tal overdose and DRG were harvested as previously
described [26].
Real-time RT-PCR
T h eg e n ee x p r e s s i o no ft h es e lected nine literature-
derived ROS-diabetes targets in DRG was measured
using real-time RT-PCR in duplicate. The amount of
mRNA isolated from each DRG was normalized to an
endogenous reference [Tbp: TATA box binding protein;
Δ cycle threshold (CT)].
Results
Identification of ROS-diabetes targets
A total of 1,021 unique targets were identified by SciMi-
ner from the 1,154 ROS-diabetes papers defined by the
query of ("Reactive Oxygen Species"[MeSH] AND “Dia-
betes Mellitus"[MeSH]) and confirmed by manual
review. Table 1 contains the top 10 most frequently
mentioned targets in the ROS-diabetes papers. Insulin
was the most frequently mentioned target, followed by
superoxide dismutase 1 and catalase.
The NCBI Gene2PubMed database, containing expert-
curated associations between the NCBI Gene and
PubMed databases, revealed 90 unique genes associated
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SciMiner identified 85 out of these 90 targets, indicating
a 94% recall rate. Five targets missed by SciMiner were
added to the initial ROS-diabetes target set to result in
1,026 unique targets (Additional File 2).
PPI network of the ROS-diabetes targets
The PPI network among the ROS-diabetes targets was
evaluated using MiMI interaction data. This was based
on the assumption that targets commonly related to a
certain topic are more likely to have frequent interac-
tions with each other. One hundred PPI networks were
generated for comparison using the same number of
genes (1,026) randomly selected from the complete
HUGO gene set (25,254). The PPI network of the ROS-
diabetes targets was significantly different from the
randomly generated networks indicating their strong
association with the topic “ROS and Diabetes”.T a b l e2
demonstrates that the mean number of targets with any
PPI interaction in the randomly generated target sets
was 528.9 (approximately 52% of 1,026 targets), while
the number of targets with any PPI interaction in the
ROS-diabetes target was 983 (96%). The number of tar-
gets interacting with each other was also significantly
different between the random networks (mean = 155.4)
and the ROS-diabetes network (mean = 879). Figure 1
illustrates the distributions of these measurements from
the 100 random networks with the ROS-diabetes set
depicted as a red vertical line. It is obvious that the PPI
network of the ROS-diabetes targets is significantly dif-
ferent from the random networks.
Functional enrichment analyses of the ROS-diabetes
targets
Functional enrichment analyses of the 1,026 ROS-diabetes
targets were performed to identify over-represented biolo-
gical functions of the ROS-diabetes targets. After Benja-
mini-Hochberg correction, a total of 189 molecular
functions, 450 biological processes, 73 cellular compo-
nents and 341 pathways were significantly enriched in the
ROS-diabetes targets when compared against all the
HUGO genes (see Additional Files 3, 4, 5 and 6 for the full
lists). Table 3 lists the top 3 most over-represented GO
terms and pathways ranked by p-values of Fisher’se x a c t
test: e.g., apoptosis, oxidoreductase activity and insulin
signaling pathway.
Identification of over-represented ROS-diabetes targets
To identify the ROS-diabetes targets highly over-
represented in ROS-diabetes literature, three sets of
background corpora of the same size (n = 1,154 docu-
ments) were generated using the same journal, volume
and issue approach. The overlap among the three back-
ground sets in terms of documents and identified targets
are illustrated in Figure 2. Approximately 90% of the
selected background documents were unique to the
individual set, while 50% of the identified targets were
identified in at least one of the three background docu-
ment sets. The frequencies of the identified targets were
compared among the background sets for significant dif-
ferences. None of the targets had a BH adjusted p-value
Table 1 Top 10 most frequent ROS-diabetes targets
Symbol Name #Paper Match Strings
INS insulin 503 INS | insulin | proinsulin |
SOD1 superoxide dismutase 1 368 Sod1 | SOD1 | SOD1 | *
CAT catalase 241 CAT | catalase | *
PRKCA protein kinase C, alpha 194 PKCA | PKC-alpha | *
ALB albumin 179 albumin | serum albumin |
NOX5 NADPH oxidase 5 177 NOX5 | nadph oxidase |
NOS2A nitric oxide synthase 2A 144 NOS | iNOS | Nos2 |*
XDH xanthine
dehydrogenase
133 XOR |xanthine
dehydrogenase| *
AGT angiotensinogen 131 Ang-II | ANG | AGT | AngI |
*
TNF tumor necrosis factor 120 TNFA | TNF | TNF-alpha | *
* Matching strings are truncated to fit in the table. The full contents are
available in the Additional File 2. ‘#Paper’ refers to the number of documents
in which each target was mentioned at least once.
Table 2 Summary of 100 randomly generated PPI networks
# of targets
with any
interaction
# of targets
interacting with
each other
# of direct
interactions
among targets
Max degree*
ROS-diabetes Targets 983 879 5002 173
Mean (100 networks) 528.9 155.4 165.4 25
STDEV (100 networks) 16 36.2 54.2 39.7
Z-Score 28.5 20 89.2 3.7
P-value(Z) 0 0 0 9.60E-05
T-Statistics -284.8 -200 -891.9 -37.3
P-value(T) 4.60E-146 6.70E-131 4.00E-195 4.20E-60
* Max degree refers to the number of interactions of the most highly interacting target.
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targets from the three different background sets (See
Additional File 7).
Comparisons of the ROS-diabetes targets against these
background sets revealed 53 highly over-represented
ROS-diabetes targets as listed in Table 4. These 53 tar-
gets were significant (p-value < 0.05) against all three
background sets and significant following Benjamini-
Hochberg multiple testing correction (BH adjusted
p-value < 0.05) against at least two of the three
Figure 1 Histograms of randomly generated PPI networks. The histograms illustrate the distributions of 100 randomly generated networks,
while the red line indicates the ROS-diabetes targets. The network of the ROS-diabetes targets is significantly different from the 100 randomly
generated networks, indicating the overlap of ROS-diabetes targets with respect to the topic “Reactive Oxygen Species and Diabetes”.
Table 3 Enriched functions of 1,026 ROS-diabetes targets
Category Term #target p-value Fold
Biological Processes GO metabolic process 113 3.40E-26 3.3
protein amino acid phosphorylation 98 2.90E-24 3.5
response to hypoxia 36 8.80E-24 12
Molecular Functions GO protein binding 514 2.80E-71 2.1
oxidoreductase activity 103 1.50E-31 4.2
transferase activity 148 1.70E-26 2.7
Cellular Components GO cytoplasm 381 1.50E-57 2.3
extracellular region 220 9.10E-44 2.9
mitochondrion 154 6.30E-43 3.9
Pathway Focal adhesion 75 2.40E-42 9.4
Apoptosis 49 6.70E-35 14.5
MAPK signaling pathway 73 4.30E-34 6.9
’#target’ refers to the number of ROS-diabetes targets with each biological function with Benjamini-Hochberg adjusted p-values. Fold is the ratio of targets from
the ROS-diabetes set to the complete HUGO gene set.
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the ROS-diabetes targets.
Functional enrichment analyses of the over-represented
ROS-diabetes targets
Functional enrichment analyses of the 53 ROS-diabetes
targets were performed to identify over-represented bio-
logical functions. Following Benjamini-Hochberg correc-
tion, a total of 65 molecular functions, 209 biological
processes, 26 cellular components and 108 pathways
were significantly over-represented when compared
against all the HUGO genes (see Additional Files 8, 9,
10 and 11 for the full lists). Table 5 shows the top 3
most significantly over-represented GO terms and path-
ways ranked by p-values of Fisher’s exact test. GO terms
related to oxidative stress such as “superoxide metabolic
process”, “superoxide release”, “electron carrier activity”
and “mitochondrion” were highly over-represented in
the 53 ROS-diabetes targets.
Gene expression change in diabetes
Two groups of DBA/2J mice exhibited significantly dif-
ferent levels of glycosylated hemoglobin (%GHb). The
mean ± SEM were 6.2 ± 0.3 for the non-diabetic control
group and for 14.0 ± 0.8 for the diabetic group (p-value
< 0.001), indicative of prolonged hyperglycemia in the
diabetic group [26]. DRG were harvested from these ani-
mals for gene expression assays. Nine genes were
selected from the top ranked ROS-diabetes targets:
superoxide dismutase 1 (Sod1), catalase (Cat), xanthine
dehydrogenase (Xdh), protein kinase C alpha (Prkca),
neutrophil cytosolic factor 1 (Ncf1), nitric oxide
synthase 3 (Nos3), superoxide dismutase 2 (Sod2), cyto-
chrome b-245 alpha (Cyba), and nitric oxide synthase 1
(Nos1). Eight genes exhibited differential expression
between diabetic and non-diabetic mice (p-value < 0.05)
as shown in Figure 3. Cat, Sod1, Sod2, Prkca, and Nos1
expression levels were decreased, while Ncf1, Xdh, and
Cyba expression levels were increased in diabetes.
Discussion
Reactive oxygen species (ROS) are products of normal
energy metabolism and play important roles in many
other biological processes such as the immune response
and signaling cascades [4-6]. As mediators of cellular
damage, ROS are implicated in pathogenesis of multiple
diseases including diabetic complications [27-30]. With
the aid of literature mining technology, we collected
1,026 possible ROS-related targets from a set of biome-
dical literature indexed with both ROS and diabetes.
Fifty-three targets were significantly over-represented
in the ROS-diabetes papers when compared against
Figure 2 Venn diagrams of document compositions and identified targets of the randomly generated background sets. Approximately
90% of the selected background documents were unique to individual set (A), while 50% of the identified targets were identified in at least one
of the three background document sets (B).
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Rank Symbol HUGO_ID Name #Paper BG #1 BG #2 BG #3
1 SOD1 11179 superoxide dismutase 1, soluble (amyotrophic
lateral sclerosis 1 (adult))
368 3.1E-84 2.0E-78 2.0E-78
2 CAT 1516 catalase 241 2.1E-50 3.9E-44 3.9E-44
3 NOX5 14874 NADPH oxidase, EF-hand calcium binding domain 5 177 3.1E-42 3.6E-39 2.1E-37
4 INS 6081 insulin 503 5.9E-41 2.0E-43 2.3E-39
5 XDH 12805 xanthine dehydrogenase 133 1.5E-30 1.2E-28 8.8E-28
6 PRKCA 9393 protein kinase C, alpha 194 7.1E-23 6.4E-26 8.9E-24
7 NCF1 7660 neutrophil cytosolic factor 1, (chronic
granulomatous disease, autosomal 1)
72 7.6E-19 7.7E-16 8.7E-16
8 NOS3 7876 nitric oxide synthase 3 (endothelial cell) 115 1.6E-18 3.9E-16 7.6E-18
9 SOD2 11180 superoxide dismutase 2, mitochondrial 85 2.1E-18 7.7E-16 3.8E-15
10 CYBA 2577 cytochrome b-245, alpha polypeptide 69 4.2E-17 5.0E-13 6.9E-14
11 NOS2A 7873 nitric oxide synthase 2A (inducible, hepatocytes) 144 3.9E-16 5.2E-12 4.5E-14
12 AGT 333 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 131 1.8E-14 1.4E-09 3.5E-08
13 AKR1B1 381 aldo-keto reductase family 1, member B1 (aldose reductase) 61 8.0E-13 9.5E-13 3.6E-11
14 CYBB 2578 cytochrome b-245, beta polypeptide (chronic granulomatous disease) 49 4.0E-12 2.6E-09 5.8E-11
15 NOS1 7872 nitric oxide synthase 1 (neuronal) 82 4.9E-12 3.7E-10 4.7E-09
16 NCF2 7661 neutrophil cytosolic factor 2 (65 kDa, chronic
granulomatous disease, autosomal 2)
50 2.4E-11 1.5E-09 3.8E-08
17 CYCS 19986 cytochrome c, somatic 81 8.7E-10 2.2E-10 2.1E-10
18 HBB 4827 hemoglobin, beta 101 1.4E-08 5.9E-10 2.2E-08
19 GSR 4623 glutathione reductase 61 1.4E-08 4.8E-08 4.8E-08
20 UCP1 12517 uncoupling protein 1 (mitochondrial, proton carrier) 38 4.1E-07 2.1E-06 9.7E-06
21 NOX4 7891 NADPH oxidase 4 31 6.2E-07 2.3E-04 2.7E-05
22 PARP1 270 poly (ADP-ribose) polymerase family, member 1 37 7.1E-07 1.1E-07 5.3E-05
23 UCP2 12518 uncoupling protein 2 (mitochondrial, proton carrier) 34 7.0E-07 4.5E-06 2.1E-05
24 HBA1 4823 hemoglobin, alpha 1 30 1.1E-06 1.2E-06 9.3E-06
25 ALB 399 albumin 179 7.0E-06 4.9E-06 1.7E-06
26 NOX1 7889 NADPH oxidase 1 30 8.2E-06 8.6E-06 9.7E-06
27 NFKB1 7794 nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1 (p105)
90 9.4E-06 1.2E-04 4.5E-04
28 VEGFA 12680 vascular endothelial growth factor A 57 2.6E-04 1.9E-04 4.1E-03
29 SOD3 11181 superoxide dismutase 3, extracellular 18 2.5E-04 8.1E-02 3.4E-02
30 REN 9958 renin 51 3.6E-04 2.2E-02 7.2E-02
31 MPO 7218 myeloperoxidase 28 5.7E-04 2.4E-01 5.1E-02
32 SORD 11184 sorbitol dehydrogenase 15 1.8E-03 1.9E-03 1.8E-03
33 COL4A1 2202 collagen, type IV, alpha 1 15 1.8E-03 1.3E-02 1.8E-03
34 TGFA 11765 transforming growth factor, alpha 46 2.1E-03 3.5E-02 3.5E-04
35 ACE 2707 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 69 3.8E-03 1.1E-02 1.1E-02
36 AGTR1 336 angiotensin II receptor, type 1 36 3.7E-03 4.9E-02 1.8E-03
37 G6PD 4057 glucose-6-phosphate dehydrogenase 19 5.6E-03 3.7E-01 2.1E-01
38 CP 2295 ceruloplasmin (ferroxidase) 13 6.2E-03 3.1E-01 2.9E-01
39 NCF4 7662 neutrophil cytosolic factor 4, 40kDa 16 6.7E-03 9.9E-04 9.9E-04
40 MT-CYB 7427 mitochondrially encoded cytochrome b 15 1.3E-02 1.3E-02 1.3E-01
41 DUOX1 3062 dual oxidase 1 11 2.2E-02 2.9E-01 1.1E-01
42 SERPINE1 8583 serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1
37 2.4E-02 2.5E-02 1.1E-03
43 GSTCD 25806 glutathione S-transferase, C-terminal domain containing 37 2.4E-02 3.8E-01 9.1E-02
44 COQ7 2244 coenzyme Q7 homolog, ubiquinone (yeast) 16 2.8E-02 1.9E-01 3.1E-02
45 RAC1 9801 ras-related C3 botulinum toxin substrate 1
(rho family, small GTP binding protein Rac1)
18 3.0E-02 4.3E-01 7.8E-02
46 MAOB 6834 monoamine oxidase B 10 3.9E-02 4.1E-01 4.4E-01
47 UCP3 12519 uncoupling protein 3 (mitochondrial, proton carrier) 17 4.7E-02 1.7E-02 1.8E-02
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ground set is defined, the over-represented targets may
vary widely. An ideal background set would be the
entire PubMed set; however, this is not possible due to
limited access to full texts and intense data processing.
An alternative method would be to use only abstracts in
PubMed, but this may not fully represent the literature.
Using only the abstracts, our target identification
method resulted in 21 (39%) of the 53 key ROS-diabetes
targets (Additional File 12), suggesting the benefit of
rich information in full text documents. In the present
study, background documents were randomly selected
from the same journal, volume, and issue of the 1,154
ROS-diabetes documents, which were not indexed with
“Reactive Oxygen Species"[MeSH] nor “Diabetes Melli-
tus"[MeSH]. This approach maintained the background
corpora not far from the ROS and diabetes context.
T h eg e n ee x p r e s s i o nl e v e l so fn i n et a r g e t ss e l e c t e d
from the 53 over-represented ROS-diabetes targets were
measured in diabetic and non-diabetic DRG. Our
laboratory is particularly interested in deciphering the
underlying mechanisms of diabetic neuropathy, a major
complication of diabetes. Data published by our labora-
tory both in vitro and in vivo confirm the negative
impact of oxidative stress in complication-prone neuron
tissues like DRG [7,10,18,31]. In an effort to obtain dia-
b e t i cn e u r o p a t h ys p e c i f i ct a r g e t s ,S c i M i n e rw a s
employed to further analyze a subset of the ROS-dia-
betes papers (data not shown). Nerve growth factor
(NGF) was identified as the most over-represented
target in this subset when compared to the full ROS-
diabetes set; however, NGF did not have statistical sig-
nificance (BH adjusted p-value = 0.06). The relatively
small numbers of papers and associated targets may
have contributed to this non-significance. Therefore, the
candidate targets for gene expression validation were
selected from among the 53 over-represented ROS-dia-
betes targets derived from the full ROS-diabetes corpus.
Among the tested genes, the expression levels of Cat,
Sod1, Sod2, Prkca, and Nos1 were decreased, while the
expression levels of Ncf1, Xdh, and Cyba were increased
under diabetic conditions. Cat, Sod1, and Sod2 are
responsible for protecting cells from oxidative stress by
destroying superoxides and hydrogen peroxides [8-11].
Decreased expression of these genes may result in oxi-
dative stress [32]. Increased expression of Cyba and
Ncf1, subunits of superoxide-generating nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase com-
plex [30], also supports enhanced oxidative stress. Xdh
and its inter-convertible form, Xanthine oxidase (Xod),
showed increased activity in various rat tissues under
oxidative stress conditions with diabetes [33], and also
showed increased expression in diabetic DRG in the
current study.
Unlike the above concordant genes, protein kinase C
and nitric oxide synthases did not exhibit predicted
expression changes in diabetes. Protein kinase C acti-
vates NADPH oxidase, further promoting oxidative
stress in the cell [34,35]. Decreased expression of Prkca
in our diabetic DRG is not parallel with expression
levels of other enzymes expected to increase oxidative
stress. Between the two nitric oxide synthases tested in
the present study, Nos1 (neuronal) expression was sig-
nificantly decreased (p-value < 0.001) in diabetes, while
Nos3 (endothelial) expression was not significant
(p-value = 0.06). The neuronal Nos1 is expected to play
a major role in producing nitric oxide, another type of
highly reactive free radical. Thus, with some exceptions,
the majority of the differentially expressed genes in
DRG show parallel results to the known activities of
these targets in diabetes, suggesting enhanced oxidative
stress in the diabetic DRG.
Assessment of antioxidant enzyme expression in dia-
betes has yielded a variety of results [36-40] depending
upon the duration of diabetes, the tissue studied and
other factors. In diabetic mice and rats, it is commonly
reported that superoxide dismutases are down-regulated
[37-40], where data regarding catalase are variable
[36,40]. PKC is activated in diabetes, but most papers
that examined mRNA demonstrated that its expression
is largely unchanged [41].
Among the 53 over-represented ROS-diabetes targets,
SOD1 was the most over-represented and was differen-
tially expressed under diabetic and non-diabetic condi-
tions. To the best of our knowledge, no published study
has investigated the role of SOD1 in the onset and/or
progression of diabetic neuropathy. Mutations of SOD1
have long been associated with the inherited form of
Table 4 53 targets over-represented in ROS-diabetes literature (Continued)
48 VCAM1 12663 vascular cell adhesion molecule 1 29 5.4E-02 6.3E-02 3.5E-02
49 AKT1 391 v-akt murine thymoma viral oncogene homolog 1 75 5.5E-02 4.9E-02 6.4E-02
50 LEPR 6554 leptin receptor 21 8.7E-02 3.1E-01 1.4E-02
51 EDN1 3176 endothelin 1 38 8.8E-02 3.8E-01 2.6E-02
52 COL1A1 2197 collagen, type I, alpha 1 84 8.7E-02 2.6E-02 1.7E-01
53 CCL2 10618 chemokine (C-C motif) ligand 2 38 2.0E-01 4.9E-02 1.0E-02
’#Paper’ is the number of papers in ROS-diabetes corpus; BG#1, BG#2 and BG#3 are Benjamini-Hochberg adjusted p-values between ROS-diabetes targets and
background sets.
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of oxidative stress-based aging [43]. Early reports indi-
cate that knockout of the SOD1 gene does not affect
nervous system development [44], although recovery fol-
lowing injury is slow and incomplete [45,46]. With
respect to diabetes, SOD1 KO accelerates the develop-
ment of diabetic nephropathy [47] and cataract forma-
tion [48]. Thus, examining the SOD1 KO mouse as a
model of diabetic neuropathy would be a reasonable fol-
low-up study.
One limitation of the current approach using literature
mining technology is incorrect or missed identification
of the mentioned targets within the literature. Based on
a performance evaluation using a standard text set Bio-
CreAtIvE (Critical Assessment of Information Extraction
systems in Biology) version 2 [49], SciMiner achieved
87.1% recall (percentage identification of targets in the
given text), 71.3% precision (percentage accuracy of
identified target) and 75.8% F-measure (harmonious
average of recall and precision = (2 × recall × preci-
sion)/(recall + precision)) before manual revision [14].
In order to improve the accuracy of SciMiner’sr e s u l t s ,
each target was manually reviewed and corrected by
checking the sentences in which each target was identi-
fied. Approximately, 120 targets (~10% of the initially
identified targets from the ROS-diabetes papers) were
removed during the manual review process. The overall
accuracy is expected to improve through the review pro-
cess; however, the review process did not address targets
missed by SciMiner, since we did not thoroughly review
individual papers. Instead, 5 missed targets, whose asso-
ciations with ROS-diabetes literature were available in
the NCBI Gene2PubMed database, were added to the
final ROS-diabetes target list (Additional File 2).
Table 5 Enriched functions of the 53 over-represented targets in diabetes
Category Term # target p-value Fold
Biological Processes GO superoxide metabolic process 7 3.70E-15 303
electron transport 13 1.50E-12 16
superoxide release 5 4.20E-11 298
Molecular Functions GO electron carrier activity 15 1.80E-17 27
oxidoreductase activity 18 2.20E-16 14
iron ion binding 15 4.20E-16 21
Cellular Components GO mitochondrion 13 9.90E-08 6
extracellular space 10 6.60E-07 8
soluble fraction 7 3.20E-06 11
Pathway Leukocyte transendothelial migration 9 6.40E-12 36
Small cell lung cancer 7 1.00E-09 38
Formation of Platelet plug 6 1.10E-08 41
’#target’ refers to the number of ROS-diabetes targets with each biological function with Benjamini-Hochberg adjusted p-values. Fold is the ratio of targets from
the ROS-diabetes set to the complete HUGO gene set.
Figure 3 Gene expression levels of selected ROS-diabetes targets in DRG examined by real-time RT-PCR. Expression levels are relative to
Tbp, an internal control (error bar = SEM) (*, p < 0.05; **, p < 0.01; ***, p < 0.001). Eight (Cat, Sod1, Ncf1, Xdh, Sod2, Cyba, Prkca, and Nos1) out
of the nine selected ROS-diabetes genes were significantly regulated by diabetes.
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The present approach enabled us to collect a compre-
hensive list of ROS and diabetes related targets and led
us to confirm the biological relevance to diabetic neuro-
pathy of the selected ROS-diabetes targets. Using SciMi-
ner to identify significantly enriched targets is applicable
to other disease topics of interest by providing a more
focused subset of literature for review and by highlight-
ing targets common to multiple manuscripts.
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